Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30024032 | 1.00 | CYP1A2 (0.56) | CYP1A2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5991804 | 0.91 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL2817506 | 0.90 | CYP1A2 (0.51) | CYP1A2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5164310 | 0.90 | BACE1 (0.54) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL5991077 | 0.87 | PKM (0.51) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL26604899 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL14572101 | 0.86 | L3MBTL1 (0.53) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL30954335 | 0.85 | CYP4F2 (0.55) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL5734037 | 0.85 | CYP4F2 (0.55) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL8837186 | 0.84 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2025-02-20 | — | — | US | disclosed |
| CN-117897376-A | Heterocyclic compounds and process for preparing same | 光明智慧生物科学公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4347561-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | Bright Minds Biosciences Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022246554-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2022-12-01 | — | — | WO | disclosed |
| CN-1315805-C | Compositions and methods of use thereof achiral analogues of CC-1065 and duocarmycins | TAIHO PHARMACEUTICAL CO LTD (GB) | 2007-05-16 | — | — | CN | disclosed |
| EP-1320522-B8 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | LEE MOSES (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1320522-B1 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | EP | disclosed |
| CN-1461298-A | Compositions and methods of use thereof achiral analogues of CC-1065 and duocarmycins | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-12-10 | — | — | CN | disclosed |
| US-6660742-B2 | Alkylation therapy; anticancer agent | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| EP-1320522-A2 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | MEDIMMUNE LIMITED (GB) | 2003-04-17 | — | — | US | disclosed |
| WO-2002030894-A2 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | OPRL1, OPRK1, CNR2 | CYP1A2 74/4885MEN1 3422/4885KMT2A 4068/4885 |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | DDB1, ERCC2, SSU72 | CYP1A2 4126/4885MEN1 1970/4885KMT2A 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.